文献速递甲状腺核医学肿瘤 PET/CT骨显像与常规 SPECT

68Ga-DOTATATE PET/CT在复发性甲状腺髓样癌中与111In-奥曲肽SPECT/CT及常规影像的逐病灶比较

68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2017-04-20

该前瞻性研究纳入15例甲状腺切除术后降钙素升高但常规影像阴性的甲状腺髓样癌患者,比较68Ga-DOTATATE PET/CT、111In-奥曲肽SPECT/CT与常规影像的病灶检出率。PET/CT检出14/15例复发,灵敏度100%、准确率93%;SPECT/CT灵敏度46%、准确率53%;PET/CT与常规影像检出病灶数无显著差异,但PET/CT检出更多骨病灶。

要点

  • 68Ga-DOTATATE PET/CT检出14/15例复发,灵敏度100%、准确率93%。
  • 111In-奥曲肽SPECT/CT检出6/15例,灵敏度46%、准确率53%。
  • PET/CT检出112个病灶,显著多于SPECT/CT的16个(p=0.005)。

核心结论

  • 68Ga-DOTATATE PET/CT在检出复发性甲状腺髓样癌病灶数方面优于111In-奥曲肽SPECT/CT。
  • 68Ga-DOTATATE PET/CT在显示骨转移方面检出率优于常规影像。

研究设计与样本

  • 前瞻性研究纳入15例甲状腺切除术后降钙素升高和/或常规影像提示复发的甲状腺髓样癌患者。
  • 患者接受68Ga-DOTATATE PET/CT、111In-奥曲肽SPECT/CT和常规影像检查。
  • 以组织病理学、常规影像及生化/临床/影像随访为参考标准。
  • 采用基于病灶和基于器官的分析进行比较。

主要发现

  • PET/CT检出14/15例复发,13例真阳性、1例真阴性、1例假阳性、无假阴性,灵敏度和准确率分别为100%和93%。
  • SPECT/CT阳性6/15例,6例真阳性、2例真阴性、7例假阴性、无假阳性,灵敏度和准确率分别为46%和53%。
  • 常规影像检出14/15例肿瘤病灶,13例真阳性、1例真阴性、1例假阳性、无假阴性,灵敏度和准确率分别为100%和93%。
  • PET/CT检出112个病灶、常规影像检出109个病灶,均显著多于SPECT/CT的16个(p=0.005)。
  • PET/CT与常规影像检出的病灶总数无显著差异(p=0.734)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: The aim of this study was to prospectively compare the detection rate of 68Ga-DOTATATE PET-CT with 111In-octreotide SPECT-CT and conventional imaging (CI) in medullary thyroid carcinoma (MTC) patients with increased calcitonin (Ctn) levels but negative CI after thyroidectomy. METHODS: Fifteen patients with raised Ctn levels and/or CI evidence of recurrence underwent 68Ga-DOTATATE PET-CT, 111In-octreotide SPECT-CT and CI. Histopathology, CI and biochemical/clinical/imaging follow-up were used as the reference standard. PET/CT, SPECT/CT and CI were compared in a lesion-based and organ-based analysis. RESULTS: PET/CT evidenced recurrence in 14 of 15 patients. There were 13 true positive (TP), 1 true negative (TN), 1 false positive (FP) and no false negative (FN) cases, resulting in a sensitivity and accuracy of 100% and 93%. SPECT/CT was positive in 6 of 15 cases. There were 6 TP, 2 TN, 7 FN and no FP cases, resulting in a sensitivity of 46% and accuracy of 53%. CI procedures detected tumor lesions in 14 of 15 patients. There were 13 TP, 1TN, 1 FP and no FN cases with a sensitivity of 100% and accuracy of 93%. A significantly higher number of lesions was detected by PET/CT (112 lesions, p = 0.005) and CI (109 lesions, p = 0.005) in comparison to SPECT/CT (16 lesions). There was no significant difference between PET/CT and CI for the total number of detected lesions (p = 0.734). PET/CT detected more lesions than SPECT/CT regardless of the organ. PET/CT detected more bone lesions but missed some neck nodal metastases evidenced by CI. The number of lesions per region demonstrated by PET/CT and CI were similar in the other sites. CONCLUSION: 68Ga-DOTATATE PET/CT is superior to 111In-octreotide SPECT/CT for the detection of recurrent MTC demonstrating a significantly higher number of lesions. 68Ga-DOTATATE PET/CT showed a superior detection rate compared to CI in demonstrating bone metastases.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Yamaga LYI, Cunha ML, Campos Neto GC, et al. 68Ga-DOTATATE PET/CT in recurrent medullary thyroid carcinoma: a lesion-by-lesion comparison with 111In-octreotide SPECT/CT and conventional imaging. Eur J Nucl Med Mol Imaging. 2017. PMID: 28429044. doi:10.1007/s00259-017-3701-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。